Kelsey A. Toth

ORCID: 0000-0001-8536-4628
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Immune Cell Function and Interaction
  • interferon and immune responses
  • Immune Response and Inflammation
  • Cancer, Hypoxia, and Metabolism
  • T-cell and B-cell Immunology
  • Genomics, phytochemicals, and oxidative stress
  • Immune cells in cancer
  • Immunotherapy and Immune Responses
  • Transplantation: Methods and Outcomes
  • Immunodeficiency and Autoimmune Disorders
  • Neutrophil, Myeloperoxidase and Oxidative Mechanisms
  • Cancer Immunotherapy and Biomarkers
  • RNA Research and Splicing
  • Cancer-related molecular mechanisms research
  • Bladder and Urothelial Cancer Treatments
  • Viral gastroenteritis research and epidemiology
  • Cytomegalovirus and herpesvirus research
  • CAR-T cell therapy research
  • Redox biology and oxidative stress
  • Virus-based gene therapy research
  • Psoriasis: Treatment and Pathogenesis
  • Cytokine Signaling Pathways and Interactions
  • Epigenetics and DNA Methylation
  • Dermatology and Skin Diseases
  • Cancer Genomics and Diagnostics

Washington University in St. Louis
2013-2024

Center for Rheumatology
2022

Medical College of Wisconsin
2012

Howard Hughes Medical Institute
2012

University of Pennsylvania
2012

University of California, San Diego
2012

Semmelweis University
2008

Memory T lymphocytes are commonly viewed as a major barrier for long-term survival of organ allografts and thought to accelerate rejection responses due their rapid infiltration into allografts, low threshold activation, ability produce inflammatory mediators. Because memory cells usually associated with rejection, preclinical protocols have been developed target this population in transplant recipients. Here, using murine model, we found that costimulatory blockade–mediated lung allograft...

10.1172/jci71359 article EN Journal of Clinical Investigation 2014-02-24

Germline gain-of-function (GOF) variants in STAT3 cause an inborn error of immunity associated with early-onset poly-autoimmunity and immune dysregulation. To study tissue-specific dysregulation, we used a mouse model carrying missense variant (p.G421R) that causes human disease. We observed spontaneous imiquimod (IMQ)-induced skin inflammation cell-intrinsic local Th17 responses GOF mice. CD4+ T cells were sufficient to drive showed increased Il22 expression expanded clones. Certain aspects...

10.1084/jem.20232091 article EN The Journal of Experimental Medicine 2024-06-11

Abstract There is an unmet need for new therapies to promote mucosal healing and restoration of epithelial barrier function in inflammatory bowel disease (IBD). Major therapeutics IBD act systemically; however, the development novel approaches specifically deliver a therapy gut has theoretical advantage optimizing benefit while limiting side effects. Adenoviral (Ad) gene been successful treating cancer recently used clinical trials as vaccine SARS-Cov2. Ad vectors can be modified target...

10.1093/ibd/izae282.065 article EN Inflammatory Bowel Diseases 2025-02-01

Primary immune regulatory disorders (PIRD) represent a group of characterized by dysregulation, presenting with wide range clinical disease, including autoimmunity, autoinflammation, or lymphoproliferation. Autosomal dominant germline gain-of-function (GOF) variants in STAT3 result PIRD broad spectrum. Studies patients have documented decreased frequency FOXP3+ Tregs and an increased Th17 cells some active disease. However, the mechanisms disease pathogenesis GOF syndrome remain largely...

10.1172/jci.insight.162695 article EN cc-by JCI Insight 2022-09-22

Non-small cell lung cancer (NSCLC) is the leading cause of cancer-related deaths worldwide and results from a complex interaction between carcinogen exposure inherent susceptibility. Despite its prevalence, genetic factors that predispose to development remain elusive. Inbred mouse models offer unique clinically relevant tool study contribute carcinogenesis due tumors resemble human adenocarcinoma broad strain-specific variation in incidence after administration. Here, we set out investigate...

10.1158/0008-5472.can-12-0908 article EN Cancer Research 2012-07-01

Abstract TLR agonists are effective at treating superficial cancerous lesions, but their use internally for other types of tumors remains challenging because toxicity. In this article, we report that murine and human naive CD4+ T cells sequester Pam3Cys4 (CD4+ TPam3) become primed Th1 differentiation. TPam3 encoding the OVA-specific TCR OT2, when transferred into mice bearing established TGF-β–OVA–expressing thymomas, produce high amounts IFN-γ sensitize to PD-1/programmed cell death ligand...

10.4049/jimmunol.1700396 article EN The Journal of Immunology 2017-12-06

Unlike other tumors, lung cancer appears to be poorly sensitive immunotherapy. We have recently demonstrated an alternative pathway of immunosurveillance. Our data indicate a failure the adaptive immune system mediate immunosurveillance and emphasize prominent role natural killer cells in this setting.

10.4161/onci.23563 article EN OncoImmunology 2013-03-01
Coming Soon ...